Nuvectis Pharma, Inc. (NVCT)
Nasdaq · Healthcare · Biotechnology
$21.39−2.42%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $698M
- 52-week range
- $5.55 – $29.28
- 52-week change
- +258.76%
- EPS (trailing)
- −$1.31
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 3, 2026
Fiscal year to Dec 2025
- Net income
- −$26.4M
- Diluted EPS
- −$1.32
From the company’s annual report on SEC EDGAR.
About Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Headquarters: Fort Lee, United States · 16 employees · nuvectis.com